Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHL TelemedicineSHMLF 57 Price-to-Tangible-Book is 18.21 as of Sep. 21, 2026. GuruFocus rates SHMLF with a GF Score™ of 57/100 and a GF Value™ of $12.02. The stock has 5 warning signs investors should review. Among 507 Healthcare Providers & Services companies, SHL Telemedicine ranks worse than 66.07% on this metric.
The historical rank and industry rank for SHL Telemedicine's Price-to-Tangible-Book or its related term are showing as below:
SHMLF'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.17 Med: 7.93 Max: 153.58
Current: 4.4
During the past 13 years, SHL Telemedicine's highest Price to Tangible Book Ratio was 153.58. The lowest was 4.17. And the median was 7.93.
SHMLF's Price-to-Tangible-Book is ranked worse than 66.07% of 507
companies
in the Healthcare Providers & Services industry
Industry Median: 2.54
vs SHMLF: 4.40
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
SHL Telemedicine Price-to-Tangible-Book Related Terms
SHL Telemedicine Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for SHL Telemedicine's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHMLF vs VEEV, BTSG, TEM: Price-to-Tangible-Book Comparison
For the Health Information Services subindustry, SHL Telemedicine's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SHL Telemedicine Price-to-Tangible-Book vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SHL Telemedicine's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where SHL Telemedicine's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
SHL Telemedicine (SHMLF) has a Price-to-Tangible-Book of 18.21 as of Sep. 21, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on SHL Telemedicine and its competitors. According to the industry distribution chart, SHL Telemedicine ranks #335 out of 507 companies in the Healthcare Providers & Services industry, placing it in the top 66.1%.
Is SHL Telemedicine's Price-to-Tangible-Book too high?
SHL Telemedicine's current Price-to-Tangible-Book is 18.21. The Healthcare Providers & Services industry median Price-to-Tangible-Book is 2.54. SHL Telemedicine's value of 18.21 is 616.9% above this industry median. Based on the distribution chart, SHL Telemedicine ranks #335 out of 507 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, SHL Telemedicine has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does SHL Telemedicine's Price-to-Tangible-Book compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, SHL Telemedicine ranks #335 out of 507 companies for Price-to-Tangible-Book. This places SHL Telemedicine in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.54. SHL Telemedicine's value of 18.21 is 616.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Healthcare Providers & Services company?
The median Price-to-Tangible-Book among Healthcare Providers & Services companies is 2.54, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SHL Telemedicine's current Price-to-Tangible-Book of 18.21 is 616.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on SHL Telemedicine and its competitors. For the Healthcare Providers & Services industry, the median Price-to-Tangible-Book is 2.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SHL Telemedicine's current Price-to-Tangible-Book is 18.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SHL Telemedicine stock overvalued right now?
SHL Telemedicine (SHMLF) has a current Price-to-Tangible-Book of 18.21. The stock's GF Value™ is $12.02, compared to a current price of $4.84 — trading 59.7% below its estimated fair value. The current Price-to-Tangible-Book is 18.21 and 616.9% above the Healthcare Providers & Services industry median of 2.54. SHL Telemedicine's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For SHL Telemedicine (SHMLF), the current Price-to-Tangible-Book is 18.21 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SHL Telemedicine (SHMLF) Overvalued in 2026?
Based on GuruFocus' analysis, SHL Telemedicine stock appears to be undervalued.
The current stock price of $4.84 is trading 59.7% below its estimated GF Value™ of $12.02.
Key valuation signals for SHMLF:
Price-to-Tangible-Book: 18.21
GF Value™: $12.02 vs. price of $4.84 (59.7% below fair value)
Industry Position: 616.9% above the Healthcare Providers & Services median (#335 of 507)
No single metric tells the full story. See the SHMLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. The company consists of the transmission of medical data by an individual, from a remote location to a medical call center, through telecommunication networks. The company provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments are Israel, Europe, and the rest of the world, out of which majority of revenue comes from Israel.
57GF Score
Get the complete analysis for SHMLF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHMLF has been successfully added to your 
